RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Talecris Biotherapeutics Holdings Corp. (NASDAQ:TLCR) (“Talecris” or the “Company”) today announced the closing on October 6 of its initial public offering of shares of common stock, which was priced on September 30 at a public offering price of $19.00 per share. In connection with the initial public offering, the underwriters exercised in full their option to purchase an additional 6,000,000 shares of common stock from the selling stockholder, Talecris Holdings, LLC. Talecris Holdings LLC is owned by Cerberus-Plasma Holdings, LLC, the managing member of which is Cerberus Partners, L.P., and by limited partnerships affiliated with Ampersand Ventures. As a result, a total of 56,000,000 shares were sold in the initial public offering, consisting of 28,947,368 shares by the Company and 27,052,632 shares by the selling stockholder. Net proceeds received by the Company were used to pay down debt. The Company did not receive any proceeds from the sale of shares by the selling stockholder.
